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Abstract 
Review on TPBG, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: 5T4, 5T4AG, M6P1 
HGNC (Hugo): TPBG 
Location: 6q14.1 
Local order 
Size: 7623 bp; orientation: plus strand. 
DNA/RNA 
Description 
The gene has 8 distinct introns. 
Transcription 
Transcription results in the production of 9 different 
mRNA, 8 alternatively spliced forms and 1 
unspliced form. 
The mRNA differ by truncation of the 5 prime end, 
presence or absence of 2 cassette exons, 
overlapping exons with different boundaries, 
splicing versus retention of 3 introns. 
The mRNA aAug10 variant has 2590 bp and the 
premessenger has a single exon. bAug10 has 3395 
bp and the premessenger has 3 exons, cAug10 has 
3446 bp and the premessenger has 2 exons, dAug10  
has 817 bp and the premessenger has 3 exons, 
eAug10 has 687 bp and the premessenger has 3 
exons, fAug10 has 607 bp and the premessenger 
has 3 exons, gAug10 has 591 bp and the 
premessenger has 2 exons, hAug10 has 564 bp and 
the premessenger has 2 exons, iAug10 has 568 bp 
and the premessenger has 2 exons. 
The gene has 3 transcripts or 3 splice variants as per 
Ensembl. These 3 variants are subsets of the 8 
spliced variants as per GenBAnk, bdEST, Trace 




There is evidence at the protein level. 
Description 
This is a 420-amino acid protein that contains an N-
terminal putative signal sequence, a 310-residue 
extracellular region, a membrane anchorage 
domain, and a 44-amino acid cytoplasmic tail with 
a potential phosphorylation site. The extracellular 
region has 7 potential N-glycosylation sites and 7 
leucine-rich repeats, which are located in 2 regions 
separated by a hydrophilic stretch (Myers et al., 
1994). 
Genomic sequence analysis reveals that the gene 
has 2 exons, the second of which encodes the 
protein (King et al., 1999). 
 
 
Figure 1. Adapted from Ensembl. 
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Figure 2. Adapted from NCBI. 
 
Sequence 
The sequence has 420 amino acids and a molecular 
weight of 46032 (UniProt). 
Isoforms 
There are 9 different isoforms (NCBI AceView). 
Of the 9 different isoforms, 6 are considered to be 
very good quality proteins and 3 are good quality 
proteins. 
The 9 isoforms are: 
- aAug 10, predicted protein is 593 aa long and 65,1 
kDa, and it has one leucine rich repeat N terminal 
domain, 3 leucine rich repeat domains, one leucine 
rich repeat C terminal domian and a transmembrane 
domain; 
- bAug10, predicted protein is 588 aa long and 64,3 
kDa and it has has one leucine rich repeat N 
terminal domain, 3 leucine rich repeat domains, one 
leucine rich repeat C terminal domain and a 
transmembrane domain; 
- cAug10 518 aa and 56,6 kDa and has one leucine 
rich repeat N terminal domain, 3 leucine rich repeat 
domains, one leucine rich repeat C terminal domain 
and a transmembrane domain; 
- dAug10 272 aa and 30,2 kDa and contains 3 
leucine rich repeat domains; 
- eAug10 229 aa and 23 kDa and contains no 
protein domain; 
- faug10 201 aa and 22,6 kDa and has 2 leucine rich 
repeat domains; 
- gAug10 161 aa and 17 kDa and contains no 
protein domain; 
- hAug10 117 aa and 13,2 kDa and contains no 
protein domain; 
- iAug10 105aa and 11,9 kDa and contains no 
protein domain. 
There are 2 phosphorylation sites that have been 
identified based on information summarized in 
Phosphosite Plus. The first is threonine 99 which 
was identified by mass spectrometry in the HeLa 
cervical cancer cell lines (Chen et al., 2009). 
The second site of phosphorylation is Serine 418 
identified via mass spectrometry in cervical cancer 
and identified in HeLa cervical cancer cell lines 
(Olsen et al., 2010). 
Expression 
TPBG is expressed by all types of trophoblasts by 
as early as 9 weeks of development. The gene is 
specific for trophoblastic cells except for amniotic 
epithelium. This has been demonstrated by 
immunoperoxidase staining of frozen sections.  
Expression is limited to few epithelial subtypes in 
adult tissue but is found to be widely expressed on a 
number of different carcinomas (Southall et al., 
1990). 
It has a molecular weight of 72 kD. 
It is a glycoprotein with a 42-kDa core protein with 
extensive N-linked glycosylation. 
It exists on the cell surface as a monomeric protein. 
The mature protein is membrane bound and 
consists of 310 amino acid extracellular regions 
with 7 N-linked glycosylation sites and a short 44-
amino acid cytoplasmic tails. 
There are 7 leucine rich repeats in the extracellular 
portion. 
The LRRs are believed to mediate protein-protein 
interactions (Carsberg et al., 1995). 
Localisation 
Membrane, single-pass type I membrane protein. 
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Table 1. Reactivity of monoclonal antibody 5T4 with normal human tissues. Immunohistological analysis of frozen sections. 




- Cell adhesion 
Transduction into cell lines enhances cell motility 
and decreases cell-to-cell contact, thereby playing a 
role in tumor invasion and metastases. This has 
been demonstarated in mouse fibroblasts (Carsberg 
et al., 1996). 
- Chemotaxis 
It has also been demonstrated that CXCR4-
mediated chemotaxis is regulated by 5T4 as shown 
in mouse embryonic cells. CXCR4 mediates the 
migration of cells to tissues rich in CXCL12 
(Southgate et al., 2010). 
- EMT 
The 5T4 antigen has been shown to play an 
important role in the epithelial-to-mesenchymal 
transition. The EMT is a process that occurs in 
early embryonic cells as well as metastases of 
certain cancers.  
The main events that occur during this process are a 
switch from E cadherin to N cadherin, increased 
vimentin expression, up-regulation of E cadherin 
repressor molecules such as snail and slug proteins, 
increased matrix metalloproteinases such as MMP2 
and MMP9, and cellular motility. 
The role of 5T4 in the process of EMT has been 
demonstrated in experiments on embryonic stem 
cells (Ensembl). 
- Pathways and interaction 
There is 1 interacting protein for TPBG-GIPC1 
(MINT). 
Full expression of 5T4 is found to transform mouse 
mammary epithelial cells to dendritic morphology. 
This is accompanied by loss of actin/adherin 
junctions, down regulation of ecadherin and 
changes in the cytoskeleton.  
These changes do not occur in the absence of the 
cytoplasmic tail portion of 5T4.  
G1PC is a scaffolding protein that interacts with the 
cytoplasmic tail of 5T4 and it contains the PDZ 
protein (Lee et al., 2008). PDZ domains mediate 
protein-protein interactions. 
The interaction between GIPC1 and 5T4 was 
demonstrated in HeLa cells using the yeast two 
hybrid approach by Awan et al. (2002).  
This interaction indicates a role for 5T4 in 
mediating changes within the cytoskeleton and 
thereby it's role in invasion and metastases. 
Homology 
Orthologs are present from 14 different species 
with the homology varying from 22% to 99% 
The greatest homology was with Pan troglotydes 
species (chimpanzee) with 99,68% homology based 
on the nucleic acids and 99,52% homology based 
on amino acids comparison to the human gene 
(Ensembl). 
There is 1 paralogue (Ensembl). 
Mutations 
Note 
Summary of gene variation consequences 
(Ensembl)  
There are a total of 921 variant sequences and 33 
structural variations as summarized by the Ensembl 
data base. 
This includes 6 frameshift mutations, 6 stop gained 
mutations, 3 inframe deletions, 153 misense 
variants, 2 splice region variants,111 synonymous 
variants,26 - 5 prime UTR variants,117- 3 prime 
UTR variants,22 intron variants, 179 upstream gene 
variants and 298 downstream gene variants. 
Structural variations: there are 12 copy number 
variations, 2 insertions, 2 inversions, 4 tandem 
duplications and 13 intrachromosomal breakpoints. 
 










5T4 antigen is expressed in up to 81% of gastric 
cancers. Starzynska et al. (1992) reported that the 
expression of 5T4 antigen in gastric cancer 
correlated with the presence of nodal involvement 
and distant metastases. Review of pathology 
showed a greater association of the 5T4 antigen 
with the diffuse variant of gastric cancer as opposed 
to the intestinal type or mixed pathology. 
Colorectal carcinoma 
Note 
5T4 antigen is expressed in up to 85% of colorectal 
cancers. Its presence is associated with poor 
prognosis. The antigen is found more commonly in 
tumors that present with nodal involvement or 
distant metastases. This has been demonstrated by 
IHC staining for the 5T4 antigen. According to a 
paper published by Mulder et al. (1997), the 5-year 
survival for tumors that were 5T4 positive was 
22%, compared to 75% for tumors that were 5T4 
negative. Median survival was 24 months for 5T4-
positive tumors, compared to >90 months for 5T4 
negative tumors. This indicates that 5T4 antigen 
expression can be used as an indicator of aggressive 
disease with earlier recurrence and suggests 
potential benefit from adjuvant chemotherapy as 
opposed to 5T4-negative tumors.  
Drugs and compounds: TroVax 
The first study of TroVax in colorectal cancer was 
in patients who had been previously treated with 
chemotherapy. In this dose-escalation study, 
TroVax was given to 22 colorectal cancer patients 
in an open-label phase I/II trial. Sixteen of 17 
immunologically evaluable patients showed a 5T4-
specific response. Fourteen patients demonstrated 
detectable antibody levels following vaccination. 
There was a positive association between the 
development of the antibody response and patient 
survival or time to disease progression (Mulryan et 
al., 2002). 
TroVax has also been studied in combination with 
systemic chemotherapy in colorectal cancer 
patients. Two phase 2 studies have studied this 
combination. In the first study, 12 patients recieved 
a combination of 5T4 with 5-FU, folinic acid, and 
irinotecan. Six had a partial response, and 5 had 
stable disease. Ten patients had 5T4-specific 
antibody responses (Harrop et al., 2007). 
The second study had a total of 11 patients who 
recived TroVax in combination with 5-FU/folinic 
acid and irinotecan. Six patients had either a 
complete response or stable disease, and 10 patients 
had 5-T4-specific antibody responses (Harrop et al., 
2008). 
TroVax has been studied as a single agent in 
patients scheduled for surgical resection of colon 
cancer. Sixteen patients were enrolled in this phase 
2 study. They received 2 vaccinations prior to 
surgery and 2 vaccinations after surgery. Nine 
patients had no disease recurrence at 8.4 months, 
and 13 patients mounted a 5T4-specific antibody 
response (Elkord et al., 2008). 
Renal cell carcinoma 
Note 
Griffiths et al. (2005) demonstrated the expression 
of 5T4 antigen in high levels in 20 cases of RCC. 
The sample was too small to make any conclusions 
regarding prognosis.  
The expression of 5T4 is on the membrane, making 
it a good candidate for targeted therapy in RCC. 
Phase 1 and 2 studies have demonstrated the safety 
and effectiveness of the TroVax vaccine in RCC. 
The TroVax vaccine is MVA-5T4, which is a 
modified virus carrying the 5T4 antigen and 
capable of eliciting an anti-5T4 antibody response.  
Drugs and compounds: TroVax 
Open-label phase1/2 trial of TroVax administration 
along with interferon alpha in 11 patients with 
metastatic RCC. All 11 patients mounted an 
antibody response to 5T4.  
The median time to progression was 9 months 
which was longer than that with interferon alone 
(Hawkins et al., 2009).  
A second open-label, phase 2 trial involved 23 
metatstatic RCC patients. TroVax was administered 
alone or in combination with IFN-alpha. In that 
study, 96% of patients mounted a 5T4-specific 
antibody response. One patient in the TroVax/IFN 
arm achieved a PR; 7 patients in the 
TroVax/interferon combination arm and 7 patients 
in the TroVax-alone arm achieved stable disease. 
The median PFS was 3.8 months, and the median 
OS was 12.1 months (Amato et al., 2009). 
Another phase 2 trial looked at the combination of 
TroVax with low-dose IL-2 in metastatic RCC 
patients. Twenty-five patients were enrolled in that 
study, 21 of whom mounted 5T4-specific antibody 
response. Two patients demonstrated a complete 
reponse of >36 months, 1 patient demonstrated a 
PR of 12 months, and 6 patients demonstrated 
stable disease for between 6 and 21 months. 
Median PFS was 3.37 months, and median OS was 
12.87 months (Amato et al., 2008b). 
There has been only 1 phase 3 trial to date that has 
studied TroVax in metastatic RCC patients. Amato 
et al. (2010) enrolled 733 patients in a study to 
compare TroVax with sunitib, IFN, or IL-2. 
Immune response was assessed in 590 patients, 
56% of whom had a positive 5T4-specific antibody 
response. A high 5T4 antibody response was 
associated with longer survival in the TroVax arm. 






Atlas Genet Cytogenet Oncol Haematol. 2014; 18(7) 495 
Cervical carcinoma 
Note 
It has been demonstrated that there is a relationship 
between the expression of 5T4 antigen and 
dysplastic conditions such as cervical intraepithelial 
neoplasia (CIN).  
Jones et al. (1990) showed a higher level of 5T4 
expression in CIN grade 2 and 3 as well as invasive 
cervical cancer.  
It has been postulated that the expression of 5T4 
may be directly related to the presence of the 
human papillomavirus. Jones et al. (1990) studied a 
total of 66 samples and demonstrated 100% 
expression of 5T4 in invasive cervical carcinoma. 
This indicates that 5T4 can be used as a potential 
tumor marker in cervical cancer. 
Non-small cell lung carcinoma 
Note 
Damelin et al. (2011) demonstrated that 5T4 is 
expressed in tumor-initiating cells and is associated 
with a poor prognosis in NSCLC. Expression of 
5T4 correlated with more undifferentiated 
histology, shorter time to recurrence, and worse 
overall survival. The expression of 5T4 correlated 
with markers of EMT. There were a total of 320 
tumor samples in this study, 249 of which were 
positive for the expression of 5T4 antigen. 
Ovarian cancer 
Note 
Wrigley et al. (1995) demonstrated that 71% of 
epithelial ovarian carcinomas expressed the 5T4 
antigen (total sample of 72 tumors). There was a 
significant correlation between the expression of 
5T4 antigen and advanced stage (i.e., FIGO stage 3 
and 4) and an association with poorly differentiated 
tumors. Patients whose tumors expressed 5T4 had a 
worse overall survival, had shorter disease-free 




Drugs and compounds: TroVax 
Two phase 2 trials have studied TroVax in 
castration-resistant prostate cancer patients.  
An open-label phase 2 trial by evaluated TroVax 
alone or in combination with GM-CSF in 27 
patients with castration-resistant prostate cancer. 
All 24 immunologically evaluable patients mounted 
a 5T4 antibody response. Time to progression was 
significantly greater in those who mounted a 5T4-
specific cellular response (5.6 vs. 2.3 months) 
(Amato et al., 2008a). 
A second phase 2 randomized study enrolled 25 
patients, 12 of whom were randomzied to receive 
TroVax plus docetaxel and 13 to receive docetaxel 
alone. Patients treated with TroVax plus docetaxel  
had a longer PFS (9.67 months) than those in the 
docetaxel-alone arm (5.10 months). Six of the 10 
immunologically evaluable patients mounted a 5T4 
antibody response (Harrop et al., 2013). 
Other diseases 
Note 
Association with other diseases based on cell line 
studies: GEO Profiles. 
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